Latest California Healthline Stories
Readers Have Bones To Pick, From Health System Flaws To Covering Marijuana Beat
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
State Gives Medi-Cal Enrollees Something To Smile About
More than 7 million California adults enrolled in Medi-Cal regained coverage for critical dental care, including crowns and partial dentures, this month.
Children’s Insurance, Other Health Programs Funded — For Now — In Bill
In a short-term spending bill, Congress extends money to the Children’s Health Insurance Program through March.
FDA Chief Says He’s Open To Rethinking Incentives On Orphan Drugs
The FDA’s Scott Gottlieb says the agency is focused on the big picture, and he wants to know why pharma churns out drugs for some rare diseases but not for others.
Arthritis Drugs Show How U.S. Drug Prices Defy Economics
Drugs that treat rheumatoid arthritis started out costing about $10,000 a year. Ten years later, they list for more than $40,000.
Infection Lapses Rampant In Nursing Homes But Punishment Is Rare
A Kaiser Health News analysis of federal inspection records shows that nursing home inspectors labeled mistakes in infection control as serious for only 161 of the 12,056 homes they have cited since 2014.
Bonus Tucked Into GOP Tax Bill For Those Aiming To Deduct Medical Expenses
The House sought to eliminate the tax deduction, generally used by people with serious illnesses or those who need long-term care services but it was eventually restored in the final bill — and expanded.
Biosimilars, Biologics And New Legal Challenges For RA Treatments
As biosimilar products reach the market and rival more established RA treatments, the players are exploring legal challenges involving antitrust and anti-competitive behavior.
Doing More Harm Than Good? Epidemic of Screening Burdens Nation’s Older Patients
Patients are often aggressively screened for cancer, even if they won’t live long enough to benefit.
Drug Industry Spent Millions To Squelch Talk About High Drug Prices
Last year, the pharma industry’ biggest trade group raised millions to change the conversation about drug pricing.